^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EU204

    i
    Other names: EBViNT, 4-1BB-based Adoptive T-Cell Therapy, 4-1BB-CTL, EBV-induced Natural T cell, Epstein-Barr virus induced adoptive T-Cell therapy, EU204
    Associations

    News

    Trials
    Company:
    Eutilex
    Drug class:
    CD137 agonist, CD8 T-cell agonist
    Related drugs:
    Associations

    News

    Trials
    1year
    Phase 1 trial of 4-1BB-based adoptive T-cell therapy targeting human telomerase reverse transcriptase in patients with advanced refractory solid tumors. (PubMed, Cytotherapy)
    The generation of TERTiNTs was feasible and safe and provided an interesting disease control rate in heavily pre-treated cancer patients.
    P1 data • Clinical Trial,Phase I • Journal • Metastases
    |
    CD8 (cluster of differentiation 8) • TERT (Telomerase Reverse Transcriptase)
    |
    cyclophosphamide • fludarabine IV • EU204 • EU211